160 related articles for article (PubMed ID: 28743181)
1. Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
Murata S; Yamamoto H; Naitoh H; Yamaguchi T; Kaida S; Shimizu T; Shiomi H; Naka S; Tani T; Tani M
J Surg Oncol; 2017 Dec; 116(8):1159-1165. PubMed ID: 28743181
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Shimizu T; Sonoda H; Murata S; Takebayashi K; Ohta H; Miyake T; Mekata E; Shiomi H; Naka S; Tani T
Eur J Surg Oncol; 2014 May; 40(5):521-528. PubMed ID: 24388411
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Matzinger O; Roelofsen F; Mineur L; Koswig S; Van Der Steen-Banasik EM; Van Houtte P; Haustermans K; Radosevic-Jelic L; Mueller RP; Maingon P; Collette L; Bosset JF;
Eur J Cancer; 2009 Nov; 45(16):2782-91. PubMed ID: 19643599
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M
Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
[TBL] [Abstract][Full Text] [Related]
6. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y
Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799
[TBL] [Abstract][Full Text] [Related]
7. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
Jacquet P; Averbach A; Stephens AD; Stuart OA; Chang D; Sugarbaker PH
Oncology; 1998; 55(2):130-8. PubMed ID: 9499187
[TBL] [Abstract][Full Text] [Related]
8. Gene expression changes induced by HIPEC in a murine model of gastric cancer.
Graziosi L; Mencarelli A; Renga B; Santorelli C; Cantarella F; Bugiantella W; Cavazzoni E; Donini A; Fiorucci S
In Vivo; 2012; 26(1):39-45. PubMed ID: 22210714
[TBL] [Abstract][Full Text] [Related]
9. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
Scaringi S; Kianmanesh R; Sabate JM; Facchiano E; Jouet P; Coffin B; Parmentier G; Hay JM; Flamant Y; Msika S
Eur J Surg Oncol; 2008 Nov; 34(11):1246-52. PubMed ID: 18222622
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.
Graziosi L; Cantarella F; Mingrone E; Gunnellini M; Cavazzoni E; Liberati M; Donini A
Ann Ital Chir; 2013; 84(5):551-6. PubMed ID: 24140896
[TBL] [Abstract][Full Text] [Related]
11. Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kusamura S; Baratti D; Antonucci A; Younan R; Laterza B; Oliva GD; Gavazzi C; Deraco M
Ann Surg Oncol; 2007 Dec; 14(12):3443-52. PubMed ID: 17909918
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK
Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study.
Shimizu T; Murata S; Sonoda H; Mekata E; Ohta H; Takebayashi K; Miyake T; Tani T
Mol Clin Oncol; 2014 May; 2(3):399-404. PubMed ID: 24772307
[TBL] [Abstract][Full Text] [Related]
14. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients.
Costa WL; Coimbra FJ; Ribeiro HS; Diniz AL; de Godoy AL; Begnami M; Silva MJ; Fanelli MF; Mello CA
World J Surg Oncol; 2012 Sep; 10():195. PubMed ID: 22992263
[TBL] [Abstract][Full Text] [Related]
15. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Cotte E; Passot G; Tod M; Bakrin N; Gilly FN; Steghens A; Mohamed F; Glehen O
Ann Surg Oncol; 2011 Sep; 18(9):2599-603. PubMed ID: 21424369
[TBL] [Abstract][Full Text] [Related]
16. Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma.
Zhibing W; Qinghua D; Shenglin M; Ke Z; Kan W; Xiadong L; Pengjun Z; Ruzhen Z
Hepatogastroenterology; 2013; 60(125):989-94. PubMed ID: 23598741
[TBL] [Abstract][Full Text] [Related]
17. Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Noh SH; Yoo CH; Chung HC; Roh JK; Shin DW; Min JS
Oncology; 2001; 60(1):24-30. PubMed ID: 11150904
[TBL] [Abstract][Full Text] [Related]
18. [Continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C for peritoneal dissemination in gastric cancer].
Fujimura T; Yonemura Y; Urade M; Sugiyama K; Hasegawa H; Hashimoto T; Miyata R; Matsuda Y; Katayama K; Yamaguchi A
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1415-24. PubMed ID: 2509604
[TBL] [Abstract][Full Text] [Related]
19. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
Al-Batran SE; Kerber A; Atmaca A; Dechow C; Reitsamer E; Schmidt S; Kolassa Y; Neumann A; Weidmann E; Hartmann JT; Jäger E
Onkologie; 2007 Feb; 30(1-2):29-34. PubMed ID: 17264523
[TBL] [Abstract][Full Text] [Related]
20. [Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer].
Ozeki H; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Ito Y; Imajo K; Shinagawa K
Gan To Kagaku Ryoho; 1988 Jan; 15(1):91-5. PubMed ID: 3122669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
